24 results
8-K
EX-99.1
RPHM
Reneo Pharmaceuticals Inc
7 May 24
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
4:00pm
workforce reduction of approximately 90%
The Company retained an independent financial advisor to initiate a formal process to evaluate potential … preservation activities, including workforce reductions December 2023 and February 2024.
General and administrative expenses were $4.6 million during
8-K
EX-99.1
RPHM
Reneo Pharmaceuticals Inc
28 Mar 24
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
4:00pm
, including suspension of all mavodelpar development activities and a total workforce reduction of approximately 90%
The Company retained an independent … to additional headcount and an increase of $1.7 million in severance payments related to our workforce reduction in December 2023, offset by a decrease
8-K
RPHM
Reneo Pharmaceuticals Inc
23 Feb 24
Cost Associated with Exit or Disposal Activities
4:00pm
by Reneo Pharmaceuticals, Inc. (the “Company”) on December 14, 2023, the Company expects to complete a second workforce reduction of approximately 20
8-K
9cod u93hq
14 Dec 23
Cost Associated with Exit or Disposal Activities
9:26am
10-K
76w7xnn2pmn nbo4z5b7
23 Mar 22
Annual report
4:38pm
10-K
EX-10.14
4frzjlsd3psvrcawa6e
23 Mar 22
Annual report
4:38pm
10-K
EX-10.12
dcmhkuxjcodpk19odb
23 Mar 22
Annual report
4:38pm
10-Q
ryf1ygnqd5ji2z6se7
20 May 21
Quarterly report
7:00am
424B4
qd742tj720 6zi9gidl
9 Apr 21
Prospectus supplement with pricing info
4:41pm